Skip to main content

Market Overview

Ozempic Linked To Severe 'Roller Coaster Ride' Side Effects In Diabetic Patients

Share:
Ozempic Linked To Severe 'Roller Coaster Ride' Side Effects In Diabetic Patients

Diabetic patients using Ozempic report severe side effects, including stomach paralysis and pancreatitis, CTV News reports.

Jana Norman, a Type 2 diabetic, described her experience with Ozempic as a “roller-coaster ride.” She was prescribed the drug in 2019 to counteract weight gain from other medications but later developed gastroparesis or stomach paralysis. 

The 52-year-old had lost around 50 pounds during the four years of using Ozempic but was using laxatives as her body couldn't process food anymore. 

She stopped taking the medicine earlier this year for two months and her sugar levels went up even though she was on insulin and other diabetes pills. Her doctor advised reducing her Ozempic dosage, but she still had stomach issues. She hasn’t taken the medicine for two weeks now, and her sugar levels are rising again.

Ozempic, an injectable medication containing semaglutide, is marketed in Canada by Novo Nordisk. The drug lists side effects such as vomiting, reduced appetite, pancreatitis, and more.

Kate Hanna, a spokesperson for Novo Nordisk, acknowledged gastrointestinal events as common side effects of Ozempic. 

“Gastrointestinal (GI) events are well-known side effects of the GLP-1 class,” Hanna mentioned.

Dr. Tasneem Sajwani highlighted the importance of symptom monitoring for diabetic patients using GLP-1 medications like semaglutide. She noted that gastroparesis can be a complication of diabetes itself.

Image Via Shutterstock

Read Next: ‘Miracle’ Weightloss Drugs Ozempic And Mounjaro Face Lawsuit Over Alleged Gastroparesis Side Effect


Engineered by Benzinga Neuro, Edited by
Pooja Rajkumari


The GPT-4 Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you.
Learn more.


 

Related Articles

View Comments and Join the Discussion!

Posted-In: Novo Nordisk Ozempic Type- 2 diabetesBiotech News Health Care Media General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com